Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$137.8MCash on Hand
21.4mo Cash Runway
Follow MGX by emailGet an email when MGX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MGX, unsubscribe in one click. Privacy
📣 What MGX Says Is Next
first half of 2027 · “We plan to initiate the INTEGR8 global clinical trial in the first half of 2027 and provide initial clinical data, including safety, tolerability, and FVIII functional activity data, in the second half of 2027.” Third Quarter 2026 and Recent Updates MGX-001 – Hemophilia A Program”
Company press release, Nov 10, 2026 · SEC filing
fourth quarter of 2026 · “The Company remains on track to submit an IND application in the fourth quarter of 2026 for the global clinical program, and subject to regulatory clearance, initiate clinical trials in 2027.”
Company press release, Aug 10, 2026 · SEC filing
fourth quarter of 2026 · “On track for regulatory submission of MGX-001 to advance global clinical program, including an IND in the fourth quarter of 2026, and subject to regulatory clearance, initiate clinical trials in 2027.”
Company press release, May 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Metagenomi furnished its November 2026 corporate presentation as Exhibit 99.1, reporting $101.7 million in cash at end of Q3 2026 with runway anticipated into 2028, and highlighting its MGX-001 hemophilia A program. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Regulatory Announced FDA clearance of the IND for MGX-001, its lead hemophilia A program, with the INTEGR8 Phase 1/2 trial planned for the first half of 2027. Q3 2026 R&D expenses were $17.5 million and cash totaled $101.7 million, with runway into 2028. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 22, 2026 ·
Furnished a September 2026 corporate presentation as Exhibit 99.1 under Regulation FD. The presentation reports $120.7 million in cash at end of Q2 2026, with runway anticipated through Q4 2027, and highlights lead program MGX-001 in hemophilia A. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Earnings Reported Q2 2026 results with $120.7 million in cash, cash equivalents and marketable securities, runway through 4Q 2027. R&D expenses were $22.5 million and G&A $6.0 million. MGX-001 IND submission remains planned for 4Q 2026. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
MGX holds $137.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $19.3M/quarter from operations,
an estimated runway of 21.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:33 · Moderate
Cash runway 21 months +8
ATM program on file since Mar 2025 +15
Shelf registration (S-3, Mar 2025) +10
Recent financing filings on SEC EDGAR:
Mar 17, 2025 · Shelf registration with ATM program, up to $75M · S-3
Feb 12, 2024 · Underwritten offering, $94M · 424B4
Share count 37,805,669 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MGX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MGX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.